1335210-24-6

Basic information

• Product Name: (3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-d]pyrido[1,2-a]pyrazine-8-carboxylic acid
• Synonyms: Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid, 2,3,5,7,11,11a-hexahydro-6-methoxy-3-methyl-5,7-dioxo-, (3S,11aR)-;(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-3-methyl-6-(methyloxy)-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide;(3S,11AR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid
• CAS NO: 1335210-24-6
• Molecular Formula: C₁₃H₁₄N₂O₆
• Molecular Weight: 294.26006
• EINECS: -0
• Mol File: 1335210-24-6.mol

Chemical Properties

• Boiling Point: 556.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.56±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.46±0.40(Predicted)
• CAS DataBase Reference: (3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-d]pyrido[1,2-a]pyrazine-8-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-d]pyrido[1,2-a]pyrazine-8-carboxylic acid(1335210-24-6)
• EPA Substance Registry System: (3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-d]pyrido[1,2-a]pyrazine-8-carboxylic acid(1335210-24-6)

Safety Data

• Hazardous Substances Data: 1335210-24-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
(3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-d]pyrido[1,2-a]pyrazine-8-carboxylic acid is used as a building block for the synthesis of more complex molecules due to its diverse functional groups and unique structure.
Used in Pharmaceutical Sciences:
(3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-d]pyrido[1,2-a]pyrazine-8-carboxylic acid is used as a potential drug candidate for the development of new therapeutic agents, given its complex structure and the presence of various functional groups that may interact with biological targets.
Used in Materials Science:
(3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-d]pyrido[1,2-a]pyrazine-8-carboxylic acid is used as a component in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity, owing to its unique chemical structure and functional groups.

Upstream product

• 2749-11-3 (S)-Alaninol 
• 1335210-23-5 1-[2,2-bis(methyloxy)ethyl]-5-(methyloxy)-6-[(methyloxy)carbonyl]-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid 
• 41051-15-4 4-methoxyacetoacetic acid methylester 
• 127958-23-0 methyl 2-[(dimethylamino)methylene]-4-methoxy-3-oxobutanoate 
• 1335210-26-8 methyl 2-(((2,2-dimethoxyethyl)amino)methylene)-4-methoxy-3-oxobutanoate 
• 2799-17-9 (S)-1-amino-2-propanol 

Downstream Products

• 1335210-25-7 (4R,12aS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1’,2’:4,5]pyrazino[2,1-b]oxazine-9-carboxamide 
• 1051375-10-0 (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide 

Relevant articles and documents

Cabotegravir derivative with biological activity as well as preparation method and application thereof

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a cabotegravir derivative with biological activity as well as a preparation method and application thereof. The structural formula of the cabotegravir derivative is shown in the specification, wherein R1 is methyl or hydrogen; R2 is methylene, isopropyl, phenyl, benzyl, a nitrogen-containing heterocyclic ring, a sulfur-containing heterocyclic ring or an oxygen-containing heterocyclic ring; and R3 is hydrogen, methyl, ethyl, phenyl, benzyl, nitrogen-containing heterocyclic ring, sulfur-containing heterocyclic ring or oxygen-containing heterocyclic ring. The preparation method comprises the following steps of: carrying out deprotection on 1-(2, 2-dimethoxyethyl)-1, 4-dihydro-3-methoxy-4-oxo-2, 5-pyridinedicarboxylic acid-2-methyl ester to obtain aldehyde, cyclizing the aldehyde with aminobutanol, and carrying out acylation reaction on the cyclized aldehyde and an amino compound; or firstly reacting the aldehyde with an amino compound, and then cyclizing with aminopropanol; and finally, carrying out click reaction with azide to obtain a target compound. The derivative provided by the invention has proliferation inhibition activity on human tumor cells.

CONTINUES FLOW PROCESS FOR THE PREPARATION OF ACTIVE PHARMACEUTICAL INGREDIENTS - POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES AND INTERMEDIATES THEREOF

The present invention discloses continues flow process for the preparation of polycyclic carbamoyl pyridone derivatives and intermediates thereof. In particular, the present invention discloses a process for the preparation of intermediate. Formule (V).

An Efficient and Highly Diastereoselective Synthesis of GSK1265744, a Potent HIV Integrase Inhibitor

A novel synthesis of GSK1265744, a potent HIV integrase inhibitor, is described. The synthesis is highlighted by an efficient construction of the densely functionalized pyridinone core as well as a highly diastereoselective formation of the acyl oxazolidine moiety. The latter exploits the target molecules ability to chelate to Mg2+, a key feature in the integrase inhibitors mechanism of action.

PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES

The present invention relates to the preparation of carbamoylpyridone derivatives and intermediates.